Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of Mycosis Fungoides and Sezary Syndrome
NCT00002557Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Jun 1993
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide in mycosis fungoides (MF), Sézary syndrome (SS) and cutaneous T-cell lymphoma (CTCL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
etoposide
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00002557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002557.